Knnate Biopharma

Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations.  The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Announced first patient dosed in Phase 1 trial  evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors

Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results

Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Kinnate Biopharma (KNTE) Ahead of Earnings?

F-Star Therapeutics Inc

Halozyme Therapeutics

Rubius Therapeutics Inc

Spruce Biosciences

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates

SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will participate in the William Blair Biotech Focus Conference 2021, being held virtually from July 14-15, 2021.

Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021

Accomplished immunologist and veteran biopharma executive has extensive experience in advancing pre-clinical stage oncology programs into the clinic Accomplished immunologist and veteran biopharma executive has extensive experience in advancing pre-clinical stage oncology programs into the clinic

Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors

Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team

Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires

Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Nima Farzan, Chief Executive Officer of Kinnate, will provide a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference, being held virtually from June 8-11, 2021.

Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference

BioNTech SE

Connect Biopharma Holdings

Fulgent Genetics

GlaxoSmithKline

Karyopharm Therapeutics

Legend Biotech

aTyr Pharma

Eli Lilly

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China.

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

SAN FRANCISCO and SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of a $35 million Series A financing for a joint venture in China. Established with OrbiMed Asia Partners, OrbiMed Private Investments and Foresite Capital, the joint venture will be headquartered in Shanghai and enable the potential development and commercialization of certain Kinnate targeted oncology product candidates across Greater China (mainland China, Hong Kong, Taiwan, and Macau). Kinnate Biopharma will be the majority shareholder in the joint venture. The company has also announced that veteran biopharmaceutical industry executive Wenn Sun, Ph.D., has been appointed as the joint venture's Executive Chair.

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)---- $KNTE #ASCO--Data highlights pre-clinical activity of KIN-2787 in Class II and Class III BRAF-mutant models

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

SAN FRANCISCO and SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that Dr. Stephen Kaldor, one of the company's co-founders, is not being nominated for re-election to the company's Board of Directors when his term expires at the company's 2021 annual meeting of stockholders to be held June 11, 2021. Dr. Kaldor plans to focus on his duties as chairman and co-founder of a new biopharmaceutical start-up.

Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors

The stock price of Kinnate Biopharma Inc (NASDAQ: KNTE) increased by 7.37%. This is why it happened.

KNTE Stock Price Increased 7.37%: Why It Happened

Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers

Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results

SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it will be added to the Russell 2000® Index as part of the planned first quarter IPO additions scheduled to join the Russell US Indexes after US equity markets close on March 19, 2021.

Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index

Aytu BioScience

Myovant Sciences

Osmotica Pharmaceuticals Plc

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing specialty products.

Why These 4 Health Care Stocks Are Moving Today

Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in an initial public offering priced at $20 per share. The Kinnate Biopharma Analyst: Following the end of the IPO quiet period, SVB Leerink analyst Andrew Berens initiated coverage of Kinnate Biopharma with an Outperform rating and $52 price target.

Why SVB Leerink Is Bullish On Kinnate Biopharma

SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the closing of its initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 1,800,000 additional shares of its common stock, at a price to the public of $20.00 per share. Including the option exercise, the aggregate gross proceeds from the offering were $276.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares were offered by Kinnate. The shares began trading on The Nasdaq Global Select Market on December 3, 2020, under the symbol “KNTE.”

Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Fintech Acquisition Corp. V Units

Ammo

Silverback Therapeutics

Seer

17 Education & Technology Group

The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and AMMO Inc., completed uplistings on the Nasdaq.

U.S. IPO Weekly Recap: The IPO Market Is Taught A Thing Or Two In An 8 IPO Week

KNTE stock has rocketed higher by as much as 115% following the Kinnate Biopharma IPO. Here's what you should know right now.

KNTE Stock: 13 Things to Know About the Kinnate Biopharma IPO

Kinnate Biopharma shares more than doubled in their trading debut Thursday, after the company upsized its initial public offering and priced it above its proposed range. The stock, trading on Nasdaq under the ticker 'KNTE,' was last up $21.31 at $41.31.

Kinnate Biopharma stock more than doubles in trading debut

Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.

Kinnate Biopharma Stock Doubles As IPO Begins Trading

Kinnate Biopharma upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the 11.5 million it originally planned, to raise $240 million.

Kinnate Biopharma upsizes IPO and prices above range at $20 a share

SAN FRANCISCO and SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $20.00 per share. All of the shares of common stock are being offered by Kinnate. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kinnate, are expected to be $240.0 million, excluding any exercise of the underwriters' option to purchase additional shares. Kinnate's common stock is expected to begin trading on the Nasdaq Global Select Market on December 3, 2020 under the symbol “KNTE”. The offering is expected to close on December 7, 2020, subject to the satisfaction of customary closing conditions. In addition, Kinnate has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

Kinnate Biopharma Announces Pricing of Initial Public Offering

Kinnate Biopharma set terms for its initial public offering on Wednesday with plans to offer 11.5 million shares priced at $18 to $19 each. The company would raise $218.5 million at the top of that range.

News for Knnate Biopharma Stock (KNTE)